II
SGMO

Ibex Investors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ibex Investors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,603
Closed -$258K – 230
2018
Q1 		$258K Sell
13,603
-2,125
-14% -$45.4K 0.21% 177
2017
Q4 		$261K Buy
+15,728
New +$234K 0.15% 166

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ibex Investors's SGMO Position: Q2 2018 in Review

Ibex Investors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 13,603 shares — an estimated $258K sold.

Ibex Investors first reported a position in SGMO in Q4 2017 and held it in 2 quarters. The position peaked at $261K in Q4 2017. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

  • Ibex Investors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
  • Ibex Investors sold 13,603 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $258K.
  • Ibex Investors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 2 quarters.
  • Ibex Investors's SANGAMO THERAPEUTICS INC position peaked at $261K in Q4 2017.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on Ibex Investors's 13F filing for Q2 2018, filed 14 Aug 2018.